论文部分内容阅读
目的:探讨重组人粒细胞集落刺激因子(rhG-CSF)预防乳腺癌化疗后骨髓抑制的疗效。方法:将我院收治的118例拟行同一方案化疗的乳腺癌患者随机分为两组。对照组59例在出现骨髓抑制时开始使用rhG-CSF,而观察组59例则在化疗1个疗程后即开始使用rhG-CSF。比较两组骨髓抑制及生活质量的差异。结果:化疗后观察组白细胞及中性粒细胞数目下降,但其高于同期对照组,比较有统计学差异(P<0.05);化疗后观察组生活质量评分降低,但其高于同期对照组,比较有统计学差异(P<0.05)。结论:早期采用rhG-CSF可预防乳腺癌化疗后骨髓抑制,提高白细胞及中性粒细胞数目,患者生活质量也较高,值得临床选择。
Objective: To investigate the effect of recombinant human granulocyte-colony stimulating factor (rhG-CSF) on preventing myelosuppression after breast cancer chemotherapy. Methods: A total of 118 cases of breast cancer who underwent chemotherapy with the same regimen in our hospital were randomly divided into two groups. In the control group, 59 patients started to use rhG-CSF in the presence of myelosuppression, while 59 patients in the observation group started to use rhG-CSF after 1 course of chemotherapy. Differences in bone marrow suppression and quality of life between the two groups were compared. Results: After chemotherapy, the number of leukocytes and neutrophils in the observation group decreased, but it was higher than that in the control group at the same period (P <0.05); after the chemotherapy, the quality of life in the observation group decreased, but it was higher than that in the control group , There was a statistically significant difference (P <0.05). Conclusion: The early use of rhG-CSF can prevent bone marrow suppression after chemotherapy for breast cancer, improve the number of leukocytes and neutrophils, and patients with high quality of life, it is worth clinical choice.